Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
公司代碼SPRC
公司名稱Scisparc Ltd
上市日期Dec 22, 2021
CEOWeiss (Amitay)
員工數量2
證券類型Ordinary Share
年結日Dec 22
公司地址20 Raul Wallenberg Street, Tower A
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6971916
電話97236103100
網址https://scisparc.com/
公司代碼SPRC
上市日期Dec 22, 2021
CEOWeiss (Amitay)